CHENGDU, China, Oct. 11, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”) announced that the Company’s trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) was approved for marketing by the National Medical Products Administration (NMPA) for its third indication, the treatment of adult patients with epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who progressed after treatment with EGFR-tyrosine kinase inhibitor (TKI) therapy.

Sac-TMT is the first and only ADC globally to show an overall survival (OS) benefit compared with platinum doublet chemotherapy and be approved for advanced NSCLC that has progressed after only TKI therapy (second line). Currently sac-TMT monotherapy is the only regimen approved for advanced EGFR-mutant NSCLC following progression on TKI therapy or TKI therapy and platinum-based chemotherapy (used sequentially or in combination)—achieving comprehensive coverage across the TKI-resistant population.

In a pre-specified interim analysis of OS, compared with the current standard of care of platinum-based doublet chemotherapy, sac-TMT monotherapy demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and OS, and significantly extends survival outcomes for these patients. More importantly, it remains the only monotherapy regimen not based on platinum-based doublet chemotherapy approved for NSCLC following progression after TKI therapy.

The approval is based on a randomized, open-label, multi-center Phase III study (OptiTROP-Lung04) which has been selected as a late-breaking abstract (LBA) at the 2025 European Society for Medical Oncology (ESMO) Congress and will be presented as an oral report in the Presidential Symposium session (Presentation # LBA5). The OptiTROP-Lung04 study evaluates the efficacy and safety profile of sac-TMT monotherapy at 5mg/kg every other week (Q2W) as an intravenous injection versus pemetrexed plus platinum chemotherapy for the treatment of patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have failed after treatment with EGFR-TKI therapy. This is the first Phase III trial globally in a Chinese population demonstrating significant OS improvement with an ADC compared to platinum-based doublet chemotherapy in EGFR-mutant NSCLC following TKI-resistance. Sac-TMT demonstrated statistically significant and clinically meaningful improvement in both OS and PFS.

In March 2025, sac-TMT was approved for EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. Compared with current standard of care of docetaxel, sac-TMT monotherapy significantly extends the PFS and OS for these patients. Additionally, the patient enrollment for a Phase III registrational study in China of sac-TMT combined with osimertinib as first-line treatment of locally advanced or metastatic non-squamous EGFR-mutant NSCLC has been completed.

Dr. Michael Ge, CEO of Kelun-Biotech said, “We are delighted to announce the approval of the third indication for our core product, sac-TMT, marking another major milestone in lung cancer treatment. EGFR mutations are the most common oncogenic driver in lung cancer, accounting for approximately 40–50% of non-squamous NSCLC cases in China. Third-generation EGFR-TKIs are the standard first-line therapy for these patients, yet resistance inevitably develops, leaving few effective treatment options. The approval of this new indication highlights sac-TMT’s broad coverage across TKI-treated NSCLC, offering a more precise and effective treatment with a proven survival benefit for a larger patient population. Looking ahead, we are advancing the clinical development of sac-TMT in combination with osimertinib for first-line EGFR-mutant NSCLC.”

About NSCLC
Lung cancer is the leading malignant tumor in China. According to statistics from the National Cancer Center, approximately 1.06 million^[1] new lung cancer cases are diagnosed annually in the country. Pathological classification of lung cancer primarily includes non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with NSCLC being the most common pathological type, accounting for about 80–85% of all lung cancer patients. According to the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines for Diagnosis and Treatment of Non-Small Cell Lung Cancer and the Chinese Medical Association Guidelines for Clinical Diagnosis and Treatment of Lung Cancer (2025 Edition), EGFR-TKI therapy is the first-line treatment for advanced NSCLC with EGFR mutations^[2],[3]. Following resistance to EGFR-TKIs, platinum-based doublet chemotherapy remains the primary standard treatment regimen. Current treatment options demonstrate suboptimal efficacy, particularly in extending overall survival, leaving significant unmet clinical needs where there’s urgent requirement for new drugs to improve patient survival outcomes.

About Sac-TMT
Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macau, and Taiwan).

To date, three indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting), EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy and EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy. Sac-TMT is the first TROP2 ADC drug approved for marketing in lung cancer globally. In addition, the new indication application for sac-TMT for the treatment of adult patients with unresectable locally advanced, metastatic hormone receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting was accepted by the Center for Drug Evaluation of the NMPA, and was included in the priority review and approval process.

As of today, the Company has initiated 9 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab^[4] or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.

About Kelun-Biotech
Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 2 projects are in the NDA stage and more than 10 projects are in the clinical stage. The company has established one of the world’s leading proprietary ADC and novel DC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://kelun-biotech.com/. 

Report by The American Chamber of Commerce in Singapore (AmChamSG), Accenture and WEConnect International show that supplier diversity drives revenue growth, but women entrepreneurs continue to face structural barriers in procurement

SINGAPORE, Oct. 11, 2025 /PRNewswire/ — The American Chamber of Commerce in Singapore (AmChamSG), in collaboration with Accenture and WEConnect International, launched ‘The Diversity Dividend: Why it Pays to Engage Women Owned Businesses in Southeast Asia‘ at the 2025 AmChamSG SME ACCelerate Forum with Ms. Yeo Wan Ling,  Assistant Secretary-General, National Trades Union Congress (NTUC) and Member of Parliament, Punggol GRC.

The report includes analysis of the supplier diversity of 631 companies in Singapore, Vietnam and Indonesia, and found that corporate revenue growth increases by 2.2% when suppliers increase women representation in leadership by 5%. 

At the forum, Anoop Sagoo, Chief Executive Officer, Southeast Asia at Accenture, highlighted findings from the report, noting that “companies embracing supplier diversity experience tangible benefits, including enhanced performance and revenue growth. By implementing the recommendations in this report, stakeholders can unlock the full potential of women-owned businesses, fostering a more inclusive and resilient business ecosystem.”

Based on a survey of 121 women entrepreneurs in Singapore, Vietnam and Indonesia, structural barriers in the procurement environment like overly complicated processes and long payment terms continue to limit access for women entrepreneurs. 

• Only 23% of women-owned businesses in Singapore supply large buyers, compared to 34% in Vietnam and 58% in Indonesia.
• In Singapore, long payment terms or delayed payments and meeting complex procurement requirements or certifications are the biggest obstacles for women-owned businesses (70%).
• Lack of transparency in the selection process and lack of mentorship or support navigating corporate procurement processes are the biggest obstacles for women-owned businesses in Indonesia and Vietnam.
• Women-owned businesses in Singapore cited visibility and recognition in the business ecosystem as the area where they need the most support (79%).
• In Indonesia and Vietnam, training in finance, operations or marketing were highlighted as the most requested forms of support (84-86%).

“Anytime a company selects a new vendor in search of innovation, there is a risk. However, it is also a risk to hire the same vendor year over year that may or may not offer the best total value over time,” noted Elizabeth Vazquez, CEO and co-founder of WEConnect International.

Dr. Hsien-Hsien Lei, Chief Executive Officer of AmChamSG said, “Business networks can bridge the gap between MNCs, SMEs, investors and policymakers. Through platforms like the SME ACCelerate Forum, AmChamSG provides opportunities for valuable connections that are vital for opening doors for SMEs to participate in large-scale supply chains.

Supplier diversity is not just about inclusion – it is business advantage.”

Download the full report ‘The Diversity Dividend: Why it Pays to Engage Women Owned Businesses in Southeast Asia‘ here: https://amcham.com.sg/wp-content/uploads/2025/10/The-Diversity-Dividend-Final-Version-Website.pdf 

About AmCham Singapore 

Established in 1973, the American Chamber of Commerce in Singapore (AmChamSG) is the largest and the most active international business association in Singapore and Southeast Asia, with nearly 700 American and other global companies with significant U.S. business interests. AmChamSG is an independent, non-partisan business organization with the goal of offering insights and facilitating access and connections that provide members with a comprehensive understanding of the local, regional, and global operating environments. Our mission – to create value for our members by providing advocacy, community, and thought leadership. Visit: www.amcham.com.sg 

About WEConnect International
WEConnect International is the leading global non-profit dedicated to driving money into the hands of women business owners by connecting them with large corporate, multilateral and government buyers around the world. Its 180+ member buyers represent more than $4 trillion in annual purchasing power and are committed to sourcing more from women-owned businesses in over 135 countries. WEConnect International identifies, educates, registers and certifies businesses that are at least 51% womenowned, managed and controlled, providing Women’s Business Enterprise Certification in over 60 countries. With a global network of 20,000+ women-owned businesses, WEConnect International is committed to unleashing the full economic potential of women-owned businesses worldwide. Visit: www.weconnectinternational.org

Large‑platform hexagonal hub (Hextra Tech) offers superior stability and ease of grip; ISO 13485 & CE certified; launched by a leading regional diabetes distributor and 4,000+ pharmacies

ISTANBUL, Oct. 11, 2025 /PRNewswire/ — Sandstone Medical — a SteriLance Medical sub‑brand focused on diabetes self‑injection — today announced the introduction of its Easydrip™ Plus pen needles into the Turkish market through a leading regional diabetes distributor with a nationwide pharmacy network. The launch is already unlocking interest from neighbouring Middle‑East markets.

Key advantages

• Hextra Tech hexagonal hub — a broad, six‑facet platform that helps patients keep the pen steady during insertion, reducing wobble, bruising and needle bending versus conventional narrow‑hub pen needles.
• Greater dosing confidence — the enlarged contact surface promotes a consistent injection angle, supporting accurate sub‑cutaneous delivery.
• Thin‑wall cannula with silicone lubrication — minimises penetration force and shortens injection time for a gentler daily routine.

Market relevance

As the first pen needle with a patent‑protected hexagonal hub available in Turkey, Easydrip™ Plus is already attracting interest from neighbouring countries and sets a practical alternative between premium global brands and low‑end generics.

Availability & next steps

• Current channel: nationwide community pharmacies, often bundled with blood‑glucose meters.
• Planned expansion: influencer‑driven digital campaigns and e‑commerce to reach online‑first consumers across Turkey and neighbouring states.

Certifications

Easydrip™ Plus is manufactured under a strict ISO 13485 quality system and holds CE Declaration of Conformity, meeting international safety and performance standards.

Brand Relationship

Sandstone Medical is SteriLance Medical’s diabetes‑care brand focused on self‑injection. Easydrip™ products are developed and marketed by Sandstone, with SteriLance providing manufacturing and quality systems under ISO 13485.

About Sandstone and SteriLance Medical

Sandstone designs patient‑centric solutions that make daily injections steadier and more comfortable. Founded in 1993, SteriLance Medical is a global innovator in blood‑sampling and injection solutions with 200+ patents and distribution in 50+ countries.
More information: en.sandstonemed.com | en.sterilance.com 
Media & distribution enquiries: smu@sterilance.com 

HANGZHOU, China, Oct. 11, 2025 /PRNewswire/ — The LOTUS development made its global debut in Hangzhou on October 10, 2025. Transcending geographical boundaries, the project redefines premium real estate in Olympic-themed destinations by integrating emotional value into its architectural identity, creating a new skyline landmark among the world’s great cities. 

With its exceptional location and emotional resonance, LOTUS turns every window into a portal connecting residents with the world — offering an Eastern-inspired vision of refined living to global elites. Located in the Hangzhou Olympic Sports Center and developed by Zhong An Group, LOTUS overlooks the Qiantang River, faces the Sun-Moon Complex, and commands views of the Big Lotus and Small Lotus Asian Games stadiums, together shaping a world-class skyline. As a key artery within the global cityscape, it unites world-class amenities and luxury resources, positioning Hangzhou more prominently on the international stage.

LOTUS, together with global brand partners, including the planned W Hotel, forms a nearly 900,000-square-meter vertical mixed-use complex, the International Office Center (IOC). With exclusive amenities such as Michelin-starred restaurants, cloud-top clubs, sky lounges, and starlit infinity pools, it establishes a comprehensive environment of luxury living and emotional connection for global elites. LOTUS is a collaboration among three leading international architecture firms. Selected residences offer views of the Lotus Bowl stadium (subject to final unit layouts) and are carefully crafted into Olympic-themed emotional assets ranging from approximately 60 to 180 square meters in gross floor area. Refined craftsmanship and integrated smart systems build the foundation of the living space, which balances shared areas with private interiors and enriches daily life within artistically inspired settings.

All eyes are on Hangzhou. In this defining era, LOTUS welcomes discerning individuals to discover its distinctive allure.

Contact: Tel: (+86)-0571-8282 5599
For more information, please visit: http://www.zhonganjt.cn/